Plasma cell myeloma recurrent

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Corticosteroid 1 substance
Monoclonal antibody (chimeric) 1 substance
IMiD 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    DEXAMETHASONE; ISATUXIMAB; POMALIDOMIDE
    2023-508869-32-00 10 countries 2022 n=217
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 0
New trials by year
2022
1
← All indication landscapes